"Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder" FISHERS, Ind.--(BUSINESS WIRE)--Scioto ...
In this study, researchers from Japan propose "rigid-autonomous phase sequences (RAPS)" as a novel theoretical framework to explain the diverse symptoms and challenges associated with autism spectrum ...
LOUISVILLE, Colo., Feb. 24, 2025 /PRNewswire/ - (TSX: CWEB) (OTCQX: CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), a market leader in hemp extract wellness products, is ...
Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb ...
Axial Therapeutics has picked up $37.3 million to bankroll a midstage test in autism and fund further work on neurological diseases. The Woburn, Massachusetts-based biotech began the phase 2b study in ...
WOBURN, Mass.--(BUSINESS WIRE)--Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological conditions, today announced that the first ...
With the number of parents self-prescribing CBD for their children’s Autism Spectrum Disorder (ASD) rising, GCANRx has been granted permission to start Phase II Clinical Trials for a cannabinoid ...
Seaside Therapeutics Inc. has begun a Phase 3 clinical study of STX209, the company’s treatment for fragile X syndrome, the most common cause of autism. Seaside Therapeutics Inc. has begun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback